EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Short‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and NMA

Haley B Naik iD, Michael Frank Mørup, Leah Davis, Vanessa Taieb, Sandeep Kiri, Isobel Munro, Matthew Hemstock, Thrasyvoulos Tzellos, Vincent Piguet, Brian Kirby

Journal of the European Academy of Dermatology and Venereology · 2026-04 · 40 (4) · 646-657

DOI: 10.1111/jdv.70265 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 28.12.2025. Verfasst von Haley B Naik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Biological Products, Adalimumab. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study was funded by UCB., UCB Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the lack of head‐to‐head studies of approved biologic therapies in hidradenitis suppurativa (HS), a chronic, recurrent inflammatory skin disease, a systematic literature review (SLR) and network meta‐analysis (NMA) were conducted to provide insight into their comparative short‐term efficacy.

Objectives

To assess the relative efficacy of approved biologic therapies (bimekizumab 320 mg every 2 weeks [Q2W], secukinumab 300 mg Q2W and every 4 weeks [Q4W] and adalimumab 40 mg every week [QW]) at Week 12–16 in moderate‐to‐severe HS.

Methods

A clinical SLR identified randomised controlled trials until 3 rd July 2024 for inclusion in Bayesian NMAs. Two evidence networks (predominantly biologic‐naïve and biologic‐experienced) were constructed to represent populations with differing biologic treatment histories. Outcomes of interest were improved HS Clinical Response (HiSCR; ≥50%/≥75%/≥90%/100%), change from baseline (CFB) in International Hidradenitis Suppurativa Severity Score System (IHS4) and improvement from baseline of ≥55% (IHS4‐55). Percentage CFB in abscess and inflammatory nodule (AN) count and CFB in absolute draining tunnels (DT) count were also assessed.

Results

The NMA included nine trials. Bimekizumab ranked as the most efficacious treatment across all predefined efficacy outcomes in both predominantly biologic‐naïve and biologic‐experienced networks, showing consistent response levels. In the predominantly biologic‐naïve network, bimekizumab Q2W compared with secukinumab (Q4W) demonstrated significantly higher odds of response for all HiSCR outcomes (odds ratio [OR]: HiSCR50 = 1.69; HiSCR75 = 1.85; HiSCR90 = 1.62; HiSCR100 = 1.88) and IHS4‐55 (OR = 1.91), and for HiSCR75 (OR = 1.60) and HiSCR90 (OR = 1.56) compared with adalimumab QW. Similar results were observed for secukinumab Q2W and both secukinumab dosing regimens in the biologic‐experienced network. Note, adalimumab studies did not report the proportion of biologic‐experienced patients. Systematic review of safety data is required for full benefit–risk assessment and decision‐making.

Conclusions

This NMA, the first to adjust for intercurrent events in moderate‐to‐severe HS across multiple efficacy outcomes, assessed up‐to‐date data, with estimates demonstrating bimekizumab's favourable efficacy among approved biologics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaBiological ProductsAdalimumabHumansAntibodies, Monoclonal, HumanizedSeverity of Illness IndexNetwork Meta-Analysis as TopicRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

biologicshidradenitis suppurativamedical dermatologynetwork meta‐analysissystematic literature review

Substanzen

Antibodies, Monoclonal, HumanizedBiological ProductssecukinumabAdalimumabbimekizumab

Autor:innen und Institutionen

  • Department of Dermatology, University of California, San Francisco, California, USA.
  • UCB, Copenhagen, Denmark.
  • UCB, Morrisville, North Carolina, USA.
  • UCB, Colombes, France.
  • UCB, Slough, UK.
  • Source Health Economics, London, UK.

ORCID-Profile: Haley B Naik

Förderung

  • This study was funded by UCB.
  • UCB Pharma

Zitieren

APA

Naik, H. B., Mørup, M. F., Davis, L., Taieb, V., Kiri, S., Munro, I., Hemstock, M., Tzellos, T., Piguet, V., & Kirby, B. (2026). Short‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and NMA. Journal of the European Academy of Dermatology and Venereology, 40(4), 646-657. https://doi.org/10.1111/jdv.70265

Vancouver

Naik HB, Mørup MF, Davis L, Taieb V, Kiri S, Munro I, et al. Short‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and NMA. Journal of the European Academy of Dermatology and Venereology. 2026;40(4):646-657. doi:10.1111/jdv.70265

BibTeX
@article{Naik2026,
  author = {Naik, Haley B and Mørup, Michael Frank and Davis, Leah and Taieb, Vanessa and Kiri, Sandeep and Munro, Isobel and Hemstock, Matthew and Tzellos, Thrasyvoulos and Piguet, Vincent and Kirby, Brian},
  title = {Short‐term efficacy of biologics in moderate‐to‐severe hidradenitis suppurativa: A systematic review and NMA},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  volume = {40},
  number = {4},
  pages = {646--657},
  doi = {10.1111/jdv.70265}
}
Kostenlos starten →